Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Maysiglu as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maysiglu is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control as monotherapy. - Combination therapy: added to metformin when metformin alone does not achieve target HbA1c. - Adjunct to diet and exercise: helps achieve target blood glucose levels when lifestyle measures are insufficient.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory infection: cough, sore throat, or congestion. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hypoglycemia: especially when combined with insulin or sulfonylureas. - Acute kidney injury: reduced renal function in susceptible patients.

Before initiating therapy, consider the following precautions: - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests in patients with liver disease. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Concomitant hypoglycemic agents: monitor blood glucose closely to avoid hypoglycemia. - Store at room temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Insulin or sulfonylureas: risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood glucose control. - Antihypertensives: monitor blood pressure as glucose changes can influence hemodynamics. - Warfarin: occasional alterations in INR may occur; monitor coagulation parameters. - Rifampin: may reduce sitagliptin plasma levels. - Digoxin: monitor for potential increased serum concentrations.